charles river Endosafe Trillium rCR cartridges

3rd November 2015  Content supplied by: Beckman Coulter International S.A.

Over 20 Evaluation Posters Available in DxN VERIS Evidence Pack

Beckman Coulter Diagnostics has made available Issue 4 of its DxN VERIS Molecular Diagnostics Evidence Pack.  Following presentation of eight new scientific posters at the European Society for Clinical Virology meeting in Edinburgh, Scotland (September 2015), the Evidence Pack has been updated and now contains more than 20 evaluation posters presented at key infectious disease meetings across Europe.

“These independent evaluations of our DxN VERIS Molecular Diagnostics System and assays* will be of great interest to virology laboratories,” said Richard Creager, senior vice president, Molecular Diagnostics Business Unit, and chief scientific officer at Beckman Coulter Diagnostics.  “The findings underpin the workflow advantages that DxN VERIS can bring to the modern laboratory, dramatically reducing both hands-on time to first result for HIV-1, HCV, HBV and CMV viral loads.”

As stated by a UK evaluation site at the recent Beckman Coulter “Workflow Transformed: DxN VERIS a New Fully Automated System for Molecular Diagnostics” seminar held at Euromedlab, Paris (June 2015), DxN VERIS is simple to use with routine operator training taking approximately 20 minutes from start to full system operation.  DxN VERIS has all necessary consumables and reagents on-board, so tests can be up and running in less than 10 minutes, as there is no lengthy set-up.

Great savings can be made in manpower and hands-on time as extraction, amplification and detection are all undertaken in the one system.  DxN VERIS also provides true single-sample random-access allowing multiple assays and samples to be run at the same time, enabling laboratories to go from sample to first result in as little as 70 minutes.

Fully CE-marked, the system currently has assays for Human Immunodeficiency Virus (HIV-1), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and Human Cytomegalovirus (CMV)* with many other assays currently in development.  Assays are supplied in a unique, single cartridge system so, unlike traditional batch-plate systems, there are no empty wells which reduces wastage and consumable costs.

For a copy of Evidence Pack Issue 4, more information and copies of other independent evaluation studies please email



*Not for sale or distribution in the U.S.; not available in all markets. ** TaqMan® is a registered trademark of Roche Molecular Systems, Inc. Used under permission and license.

Share on:


Date Published: 3rd November 2015

View full company details

Related news